Erasca
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
41 of 41
Similar slides by Erasca
See diffirences between slides (animation)
Investor Presentation
November 2023
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Investor Presentation
August 2023
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
IPO
July 2021
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
Related slides by other companies
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase | RenovoRx
RenovoRx
IPO
August 2021
promising data from phase and observational registry studies advanced clinical development program to phase median overall survival gem alone | RenovoRx
Aeglea BioTherapeutics
Investor Presentation
October 2023
cash and anticipated milestones | Aeglea BioTherapeutics
Compass Therapeutics
Investor Presentation
May 2023
phase data responses achieved across multiple subclasses as of compass | Compass Therapeutics
Other recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
July 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights